A third generation EGFR inhibitor. Selectively inhibits mutant EGFR T790M. Inhibits EGFR phosphorylation and induces siginificant tumor regressionin murine model of EGFR T790M. WZ4002 can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more effectively than Src inhibitors.